Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03042767 · ClinicalTrials.gov registry record · Phase 2
Anti-LPS Antibody Treatment for Pediatric NAFLD
A Phase 2 study of Nonalcoholic Fatty Liver Disease (NAFLD), sponsored by Miriam Vos, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT03042767 is a Phase 2 study of Nonalcoholic Fatty Liver Disease (NAFLD) that has completed, run by Miriam Vos, MD. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03042767, a Phase 2 study of Nonalcoholic Fatty Liver Disease (NAFLD), has completed, sponsored by Miriam Vos, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The main objective of this pilot study is to evaluate whether 12 weeks of IMM-124E in children with nonalcoholic fatty liver disease (NAFLD) in combination with standard of care treatment will decrease inflammation in the liver as measured by alanine transaminase (ALT). Specifically, investigators will measure percent change in ALT from Week 0 to Week 12 in treatment compared to placebo.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL IMM-124E
Study Locations (1)
Georgia
- Children's Healthcare of Atlanta - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2019-10-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03042767
The ClinicalTrials.gov registry entry for NCT03042767 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Miriam Vos, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nonalcoholic Fatty Liver Disease (NAFLD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03042767 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT03042767 about?
NCT03042767 is a clinical study titled "Anti-LPS Antibody Treatment for Pediatric NAFLD". The main objective of this pilot study is to evaluate whether 12 weeks of IMM-124E in children with nonalcoholic fatty liver disease (NAFLD) in combination with standard of care treatment will decrease inflammation in the liver as measured by alanine transaminase (ALT). Specifically, investigators w...
What is the current status of trial NCT03042767?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2017-02-01. Estimated completion is 2019-10-23.
What conditions does trial NCT03042767 study?
This clinical trial studies the following conditions: Nonalcoholic Fatty Liver Disease (NAFLD).
What interventions are being tested in trial NCT03042767?
The interventions under investigation include: Placebo (OTHER), IMM-124E (BIOLOGICAL).
Who is sponsoring clinical trial NCT03042767?
This trial is sponsored by Miriam Vos, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03042767 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nonalcoholic Fatty Liver Disease (NAFLD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.